Evidence map›Paper›PMID 41454558›Full record

ReviewPhytotherapy research : PTR2026

Evaluation of Potential Hormonal Activities of Ashwagandha (Withania somnifera).

Günter Vollmer, Thomas Brendler

Abstract readReview
In one paragraph

Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Is Ashwagandha an Abortifacient?Phytotherapy research : PTR · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Günter VollmerFakultät Biologie, Technische Universität Dresden, Dresden, Germany.
Thomas BrendlerPharmacognosy Institute, School of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ashwagandha is a widely used herb in traditional medicine systems, particularly Ayurveda. Despite its extensive tradition, growing concerns regarding its potential endocrinological effects have prompted scientific scrutiny. This review systematically evaluates the current preclinical, clinical, and case study evidence concerning AS's effects on hormonal systems, including the thyroid axis, the hypothalamic-pituitary-adrenal (HPA) axis, and the hypothalamic-pituitary-gonadal (HPG) axis. AS appears to elevate thyroid hormones in hypothyroid contexts. Multiple studies consistently show AS-mediated reductions in cortisol levels, supporting its proposed anti-stress effects via modulation of HPA-axis activity. Evidence also indicates AS may influence sex hormone regulation in both sexes, notably increasing testosterone levels in men and affecting estrogen and gonadotrophins in women. Mechanistically, these hormonal effects likely result from modulation of central regulatory pathways rather than direct receptor binding. Limitations in existing studies-such as high dosing in animal models and small sample sizes in clinical trials-underscore the need for more rigorous, dose-responsive, and mechanistically targeted research. In the meantime, careful consideration is warranted when evaluating AS as a therapeutic agent.

Indexed as

Plant ExtractsWithaniaAnimalsFemaleHumansHypothalamic-Pituitary-Gonadal AxisHypothalamo-Hypophyseal SystemPituitary-Adrenal SystemThyroid GlandThyroid HormonesAshwagandhaPlant ExtractsThyroid Hormonesashwagandhaendocrine systemHPA axisHPG axiskisspeptinthyroidWithania somniferawithanolides

Identifiers

PMID41454558
PMCPMC13436145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.